The nearest term catalyst is an article in a prestigious journal using blinded data from the Phase 3 trial is due or even overdue now. The problem is, as with things like Hospital Exemption reimbursement negotiations, once a process is late there is a good and increasing chance that it will never happen. NWBO is famous for talking big about something and then quietly letting it fade away while investors are strung along for months or years.
After that the next catalyst would be the unblinding of the Phase 3 data and the end of the trial which is overdue since we have blown past the primary endpoint of Progression Free Survival (PFS) and the trial did not end so now we are in uncharted territory since we are waiting for better “long tail” Overall Survival numbers. The problem is that due to lack of funds NWBO does only one data analysis a year, the latest of which is just being finished now. So they could do data unblinding any day time or wait until after another analysis in Spring 2019. They could, in theory pay for a second analysis this Fall, but one given the expense etc. if we do not hear anything in a few months, it is a solid bet we will not see an end to all this.
I do not know what you mean by a “few shares” or “way back when” but if you are still interested in NWBO the price of averaging down would probably be pretty cheap and let you be in a position to recover your losses if there is any improvement in NWBO.
I am a cynic on NWBO but you have to understand that while you have been gone NWBO has diluted you severely so any realistic share price appreciation with Phase 3 Approval etc. will likely not let you recover your losses, let alone make a fair profit.
News 
Market Data 
Discover 
